NALIRIFOX as Induction Therapy in LAPC
NCT06467565
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG:
Liposomal irinotecan
Sponsor
The First Affiliated Hospital with Nanjing Medical University